The proliferation of immunomics information availability has laid the groundwork for the development of new technology platforms for antigen discovery, particularly protein marker-based proteomic detection microarrays. CD Genomics helps customers discover and identify biomarkers and build protein microarrays for sample detection such as serum and urine.
Two main strategies for defining immunomics marker discovery based on proteomics for cancer include autoantigens and autoantibodies, or the assessment of the relevance of already described markers. Tumors are thought to induce the release of many proteins into the bloodstream. Therefore, the diagnosis of cancer by serum analysis based on immunomics is an attractive concept. In addition to tumor-specific expressed antigens, tumor point mutation antigens such as p53, differentiation proteins, and certain antigens overexpressed in tumors, humoral immune responses in patient sera that specifically recognize tumor-associated antigens are also important directions of immunohistology for biomarker discovery.
Rapid and accurate in vitro diagnosis of all infectious diseases, including viral, bacterial, and parasitic infections, has received increasing attention. Novel biomarkers of pathogens are identified by using an integrated approach, a high-throughput screening of the predictive immunome. The diagnostic performance of a subset of antigens is then validated by ELISA and other experiments to discover the most sensitive and specific antigens. Finally, the highest performing homologous antigens of validated biomarkers are used as inexpensive and available effective diagnostic tools for infectious diseases.
Autoimmune diseases are a group of disorders characterized by disordered stimulation of auto-reactive immune responses that attack their own organs or tissues. To date, a variety of microarrays based on immunomics have been widely used to discover and identify potential biomarkers for multiple diseases. Similar multiplex methods have now been developed to screen for specific autoantibody biomarkers for various autoimmune diseases, such as rheumatoid disease, type 1 diabetes, lupus nephritis, multiple sclerosis, and so on. The most well-studied autoantigens will be used to construct the assay to screen for autoantibodies in patient serum.
Typically, the identification of additional biomarkers will help to improve the accuracy of determining a patient's diagnosis. With the rapid development of technology and the accumulation of various biological materials, more and more protein arrays are used to screen and identify biomarkers for various diseases and are used for disease diagnosis. CD Genomics provides specialized immunomics services to help clients discover and identify specific biomarkers and help to build microarrays for disease diagnosis.
To facilitate your special project, our biomarker development solutions team provides cutting-edge research tools, industry insight, and in-depth expertise.
CD Genomics' wide range of immunomics and proteomics solutions can help you achieve your key research goals for biomarker discovery and drug development. Based on our technologies and workflows, our immunomics applications will provide you with the key insights you need to advance your research, no matter what your research goals are. Please contact us for more information.
